The Concept of Heart Failure: Chronic Diseases Accompanied by an Attack of Acute Exacerbation

Kato, Masashi

doi:10.1007/978-4-431-56065-4_1

Therapeutic Strategies for Heart Failure 2017

DOI: 10.1007/978-4-431-56065-4_1

|View full text |Cite

The Concept of Heart Failure: Chronic Diseases Accompanied by an Attack of Acute Exacerbation

Masashi Kato

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2018

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Pharmacotherapy of Chronic Heart Failure

Upnitskiy

2018

Biomed. Pharmacol. J.

View full text Add to dashboard Cite

The aspects of chronic heart failure treatment in age-related risk group are described in the present article. It is established that the optimal treatment duration is 6-12 months. The authors focused on pharmacotherapeutic part only, excluding active application of invasive treatment and diagnostics methods. The analysis of long-term therapy in three parallel groups defined the role of both blood pressure control and pharmacodynamics specifics of the drugs in clinical positive dynamics of the disease development and reverse heart and vessels remodeling. Indication of spironolactone along with the basic blood pressure control therapy increased tolerance to physical loads, improved quality of life in patients with chronic heart failure (CHF), accelerated recovery rate of the disturbed circadian rhythm of blood pressure, significantly reduced left ventricle dimensions and left atrium dilation reversion, decreased systolic blood pressure in pulmonary artery due to significant improvement of left ventricle diastolic function. Indication of trimetazidine in combination with spironolactone lowered functional class of the disease by New York Heart Association (NYHA) functional classification in 66.7% of cases and increased glomerular filtration rate. Nephroprotective activity of trimetazidine confirmed the fact that 80% of patients were rediagnosed with lower stage of chronic kidney disease after the therapy.

show abstract

Pharmacotherapy of Chronic Heart Failure

Upnitskiy

2018

Biomed. Pharmacol. J.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The Concept of Heart Failure: Chronic Diseases Accompanied by an Attack of Acute Exacerbation

Cited by 1 publication

References 28 publications

Pharmacotherapy of Chronic Heart Failure

Pharmacotherapy of Chronic Heart Failure

Contact Info

Product

Resources

About